Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Meaningful Improvement and Worsening in Patients Who Do Not Achieve Low Disease Activity and Switch Therapy to a New Biologic or Targeted Disease-Modifying Antirheumatic Drug: Results From the CorEvitas RA Registry.
Curtis JR, Fiore S, Ford K, Janak JC, Chang H, Pappas DA, Blachley T, Emeanuru K, Bykerk VP. Curtis JR, et al. Among authors: blachley t. J Clin Rheumatol. 2023 Jun 1;29(4):e47-e51. doi: 10.1097/RHU.0000000000001956. Epub 2023 Mar 24. J Clin Rheumatol. 2023. PMID: 37000177
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Pappas DA, et al. Among authors: blachley t. Ann Rheum Dis. 2021 Jan;80(1):96-102. doi: 10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21. Ann Rheum Dis. 2021. PMID: 32719038 Free PMC article.
Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng et al.
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM. Pappas DA, et al. Among authors: blachley t. Ann Rheum Dis. 2022 Nov;81(11):e225. doi: 10.1136/annrheumdis-2020-218907. Epub 2020 Nov 11. Ann Rheum Dis. 2022. PMID: 33177102 No abstract available.
49 results